Role of insulin-like growth factor binding protein-3 in breast cancer cell growth

Microscopy Research and Technique

Volumn 59, Issue 1, 2002, Pages 12-22

  Schedlich, Lynette J ^a,c   Graham, Lloyd D ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b CSIRO   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Antiproliferative activity; Apoptosis; Cell signaling; Growth factor; Nuclear hormone; Nuclear import

Indexed keywords

CANCER CELLS; CELL DEATH; CELL MEMBRANES; DISEASES; ENDOCRINOLOGY; INSULIN; PHYSIOLOGY; PROTEINS; SIGNALING;

ANTIPROLIFERATIVE ACTIVITIES; BREAST CANCER CELLS; CELLS SIGNALING; GROWTH FACTOR; GROWTH HORMONES; INSULIN-LIKE GROWTH FACTOR; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS-3; NUCLEAR HORMONES; NUCLEAR IMPORT; TRANSFORMING GROWTH FACTORS;

CELL SIGNALING;

CALCITRIOL; GROWTH FACTOR; PROTEIN P53; RETINOIC ACID; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

EID: 0036785224     PISSN: 1059910X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jemt.10173     Document Type: Article

References (118)

1. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT Jr, LeRoith D, Fontana JA. 1992. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 131:1858-1866.
2. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. 1998. The p53 network. J Biol Chem 273:1-4.
3. Albiston AL, Saffery R, Herington AC. 1995. Cloning and characterization of the promoter for the rat insulin-like growth factor binding protein-3 gene. Endocrinology 136:696-704.
4. Bates S, Vousden KH. 1996. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6:12-18.
5. Baxter RC. 1993. Circulating binding proteins for the insulin-like growth factors. Trends Endocrinol Metab 4:91-96.
6. Baxter RC. 1995. Insulin-like growth factor-binding proteins as glucoregulators. Metab Clin Exp 44:12-17.
7. Baxter RC. 1997. Molecular aspects of the insulin-like growth-factor binding proteins. In: LeRoith D, editor. Advances in molecular and cellular endocrinology. Greenwich, CT: JAI Press. p 123-159.
8. Bejcek BE, Li DY, Deuel TF. 1989. Transformation by v-sis occurs by an internal autoactivation mechanism. Science 245:1496-1499.
9. Bikle DD. 1992. Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13:765-784.
10. Bogdan C, Ding A. 1992. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J Leukoc Biol 52:119-121.
11. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EEO, Weiler J, Bar RS. 1995. IGFBP-3 and IGFBP-5 association with endothelial cells: Role of C-terminal heparin binding domain. Growth Regul 5:1-17.
12. Bourdon JC, Deguin-Chambon V, Lelong JC, Dessen P, May P, Debuire B, May E. 1997. Further characterisation of the p53 responsive element - identification of new candidate genes for transactivation by p53. Oncogene 14:85-94.
13. Bourhis XL, Toillon RA, Boilly B, Hondermarck H. 2000. Autocrine and paracrine growth inhibitors of breast cancer cells. Breast Cancer Res Treat 60:251-258.
14. Boyle BJ, Zhao XY, Cohen P, Feldman D. 2001. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-1324.
15. Bruning PF, Vandoorn J, Bonfrer JMG, Vannoord PAH, Korse CM, Linders TC, Hart AAM. 1995. Insulin-like growth factor-binding protein-3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62:266-270.
16. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
17. Butt AJ, Firth SM, King MA, Baxter RC. 2000. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells. J Biol Chem 275:39174-39181.
18. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR. 1998. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol 275:E321-331.
19. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. 1999. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 274:30215-30221.
20. Chan JM, Stampfer MJ, Giovannucci E, Ma J, Pollak M. 2000. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and prostate cancer risk: epidemiological studies. Growth Hormone IGF Res 10:S32-33.
21. Chen JC, Shao ZM, Sheikh MS, Hussain A, Leroith D, Roberts CT, Fontana JA. 1994. Insulin-like growth factor-binding protein enhancement of insulin-like growth factor-I (IGF-I)-mediated DNA synthesis and IGF-I binding in a human breast carcinoma cell line. J Cell Physiol 158:69-78.
22. Colston KW, Perks CM, Xie SP, Holly JM. 1998. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor-binding protein-3. J Mol Endocrinol 20:157-162.
23. Conover CA. 1991. Glycosylation of insulin-like growth factor-binding protein-3 (IGFBP-3) is not required for potentiation of IGF-I action: evidence for processing of cell-bound IGFBP-3. Endocrinology 129:3259-3268.
24. Conover CA, Ronk M, Lombana F, Powell DR. 1990. Structural and biological characterization of bovine insulin-like growth factor-binding protein-3. Endocrinology 127:2795-2803.
25. Cullen KJ, Lippman ME, Chow D, Hill S, Rosen N, Zwiebel JA. 1992. Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression. Mol Endocrinol 6:91-100.
26. Daly RJ, King RJ, Darbre PD. 1990. Interaction of growth factors during progression towards steroid independence in T47D human breast cancer cells. J Cell Biochem 43:199-211.
27. Devi GR, Yang DH, Rosenfeld RG, Oh Y. 2000. Differential effects of insulin-like growth factor (IGF) binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology 141:4171-4179.
28. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. 2000. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60:2304-2312.
29. Dingwall C, Laskey R. 1992. The nuclear membrane. Science 258:942-947.
30. Fanayan S, Firth SM, Butt AJ, Baxter RC. 2000. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J Biol Chem 275:39146-39151.
31. Figueroa JA, Jackson JG, Mcguire WL, Krywicki RF, Yee D. 1993. Expression of insulin-like growth factor-binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 52:196-205.
32. Firth SM, Fanayan S, Benn D, Baxter RC. 1998a. Development of resistance to insulin-like growth factor-binding protein-3 in transfected T47D breast cancer cells. Biochem Biophys Res Commun 246:325-329.
33. Firth SM, Ganeshprasad U, Baxter RC. 1998b. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273:2631-2638.
34. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D. 1991. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 128:1115-1122.
35. Fowke PJ, Hodgkinson SC. 1996. The ovine pancreatic protein which binds insulin-like growth factor-binding protein-3 is procarboxypeptidase A. J Endocrinol 150:51-56.
36. Fowler CA, Perks CM, Newcomb PV, Savage PB, Farndon JR, Holly JM. 2000. Insulin-like growth factor-binding protein-3 (IGFBP-3) potentiates paclitaxel-induced apoptosis in human breast cancer cells. Int J Cancer 88:448-453.
37. Friedlander P, Haupt Y, Prives C, Oren M. 1996. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 16:4961-4971.
38. Gill ZP, Perks CM, Newcomb PV, Holly J. 1997. Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272:25602-25607.
39. Gualandris A, Coltrini D, Bergonzoni L, Isacchi A, Tenca S, Ginelli B, Presta M. 1993. The NH2-terminal extension of high molecular weight forms of basic fibroblast growth factor (bFGF) is not essential for the binding of bFGF to nuclear chromatin in transfected NIH 3T3 cells. Growth Factors 8:49-60.
40. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. 1996. Insulin-like growth factor-binding protein-3 mediates retinoic acid-and transforming growth factor beta-2-induced growth inhibition in human breast cancer cells. Cancer Res 56:1545-1550.
41. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M. 1998. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396.
42. Henderson JE, Amizuka N, Warshawsky H, Biasotto D, Lanske BM, Goltzman D, Karaplis AC. 1995. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. Mol Cell Biol 15:4064-4075.
43. Hollowood AD, Lai T, Perks CM, Newcomb PV, Alderson D, Holly JMP. 2000. IGFBP-3 prolongs the p53 response and enhances apoptosis following UV irradiation. Int J Cancer 88:336-341.
44. Hong WK, Itri LM. 1994. The retinoids. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. New York: Raven Press. p 597-630.
45. Huynh H, Yang XF, Pollak M. 1996. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor-binding protein-3 autocrine loop in human breast cancer cells. J Biol Chem 271:1016-1021.
46. Imamura T, Engleka K, Zhan X, Tokita Y, Forough R, Roeder D, Jackson A, Maier JA, Hla T, Maciag T. 1990. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science 249:1567-1570.
47. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. 1995. Bcl-x and Bcl-2 inhibit TNF and Fas induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10:2297-2305.
48. Jans DA, Briggs LJ, Gustin SE, Jans P, Ford S, Young IG. 1997. The cytokine interleukin-5 (IL-5) effects cotransport of its receptor subunits to the nucleus in vitro. FEBS Lett 410:368-372.
49. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, Havemann K. 1997. Nuclear localization of insulin-like growth factor-binding protein-3 in a lung cancer cell line. Endocrinology 138:1767-1770.
50. Jones JI, Clemmons DR. 1995. Insulin-like growth factors and their binding proteins - biological actions. Endocr Rev 16:3-34.
51. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. 1996. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 28:619-637.
52. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. 2000. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215-244.
53. Kim MY, Linardic C, Obeid L, Hannun Y. 1991. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor alpha and gamma-interferon. Specific role in cell differentiation. J Biol Chem 266:484-489.
54. Kim HS, Nagalla SR, Oh Y, Wilson E, Roberts CT, Rosenfeld RG. 1997. Identification of a family of low affinity insulin-like growth factor-binding proteins (IGFBPs)-characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc Natl Acad Sci USA 94:12981-12986.
55. Klefstrom J, Vastrik I, Saksela E, Valle J, Eilers M, Alitalo K. 1994. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J 13:5442-5450.
56. Kliewer SA, Umesono K, Mangelsdorf DJ, Evans RM. 1992. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature 355:446-449.
57. Ko LJ, Prives C. 1996. p53: puzzle and paradigm. Genes Dev 10:1054-1072.
58. Lalou C, Lassarre C, Binoux M. 1996. Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3. Horm Res 45:156-159.
59. Lamm GM, Christofori G. 1998. Impairment of survival factor function potentiates chemotherapy-induced apoptosis in tumor cells. Cancer Res 58:801-807.
60. Leal SM, Liu Q, Huang SS, Huang JS. 1997. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein-3 receptor. J Biol Chem 272:20572-20576.
61. Leal SM, Huang SS, Huang JS. 1999. Interactions of high affinity insulin-like growth factor-binding proteins with the type V transforming growth factor-beta receptor in mink lung epithelial cells. J Biol Chem 274:6711-6717.
62. Li WL, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA. 1997. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in opossum kidney cells. Endocrinology 138:1763-1766.
63. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. 1996. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 10:142-153.
64. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. 2000. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 275:33607-33613.
65. Lobie PE, Wood TJ, Chen CM, Waters MJ, Norstedt G. 1994. Nuclear translocation and anchorage of the growth hormone receptor. J Biol Chem 269:31735-31746.
66. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. 2000. ADAM 12-S Cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 278:511-515.
67. Lotan R. 1980. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91.
68. Ludwig RL, Bates S, Vousden KH. 1996. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 16:4952-4960.
69. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. 1999. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620-625.
70. Mangelsdorf DJ, Evans RM. 1995. The RXR heterodimers and orphan receptors. Cell 83:841-850.
71. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P, Zwerschke W. 2000. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor-binding protein-3. Mol Cell Biol 20:6483-6495.
72. Martin JL, Baxter RC. 1999. Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor-binding protein-3 (IGFBP-3) in breast cancer cells. J Biol Chem 274:16407-16411.
73. Martin JL, Ballesteros M, Baxter RC. 1992. Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta 1 release IGF-binding protein-3 from human fibroblasts by different mechanisms. Endocrinology 131:1703-1710.
74. Martin JL, Coverley JA, Pattison ST, Baxter RC. 1995. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: Stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136:1219-1226.
75. Massague J, Czech MP. 1982. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 257:5038-5045.
76. Miraki-Moud F, Jenkins PJ, Fairclough PD, Jordan S, Bustin SA, Jones AM, Lowe DG, Monson JP, Grossman AB, Besser GM, Camacho-Hubner C. 2001. Increased levels of insulin-like growth factor-binding protein-2 in sera and tumors from patients with colonic neoplasia with and without acromegaly. Clin Endocrinol 54:499-508.
77. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K, Baylink DJ. 1995. Studies on the mechanisms by which insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. J Biol Chem 270:20424-20431.
78. Nickerson T, Huynh H, Pollak M. 1997. Insulin-like growth factor-binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237:690-693.
79. Obeid LM, Linardic CM, Karolak LA, Hannun YA. 1993. Programmed cell death induced by ceramide. Science 259:1769-1771.
80. O'Grady P, Huang SS, Huang JS. 1991. Expression of a new type high molecular weight receptor (type V receptor) of transforming growth factor beta in normal and transformed cells. Biochem Biophys Res Commun 179:378-385.
81. Oh Y. 1998. IGF-independent regulation of breast cancer growth by IGF-binding proteins. Breast Cancer Res Treat 47:283-293.
82. Oh Y, Muller HL, Lamson G, Rosenfeld RG. 1993a. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268:14964-14971.
83. Oh Y, Muller HL, Pham H, Rosenfeld RG. 1993b. Demonstration of receptors for insulin-like growth factor-binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268:26045-26058.
84. Oh Y, Muller HL, Ng L, Rosenfeld RG. 1995. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270:13589-13592.
85. Paik S. 1992. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 22:31-38.
86. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JM. 1999. Differential IGF-independent effects of insulin-like growth factor-binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 75:652-664.
87. Pollak M. 2000. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36:1224-1228.
88. Raffo P, Emionite L, Colucci L, Belmondo F, Moro MG, Bollag W, Toma S. 2000. Retinoid receptors: pathways of proliferation inhibition and apoptosis induction in breast cancer cell lines. Anticancer Res 20:1535-1543.
89. Rajah R, Valentinis B, Cohen P. 1997. Insulin like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta-1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181-12188.
90. Reed JC. 1994. Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1-6.
91. Rozen F, Zhang J, Pollak M. 1998. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breast cancer cells is associated with increased insulin-like growth factor-binding protein-3 accumulation. Int J Oncol 13:865-869.
92. Salahifar H, Baxter RC, Martin JL. 2000. Differential regulation of insulin-like growth factor-binding protein-3 protease activity in MCF-7 breast cancer cells by estrogen and transforming growth factor-beta1. Endocrinology 141:3104-3110.
93. Schedlich LJ, Young TF, Firth SM, Baxter RC. 1998. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273:18347-18352.
94. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. 2000. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 275:23462-23470.
95. Sell C, Baserga R, Rubin R. 1995. Insulin-like growth factor I (IGF-I) and the IGF-I receptor prevent etoposide-induced apoptosis. Cancer Res 55:303-306.
96. Shang Y, Baumrucker CR, Green MH. 1999. Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J Biol Chem 274:18005-18010.
97. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. 2000. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 275:18574-18580.
98. Skaar TC, Baumrucker CR. 1993. Regulation of insulin-like growth factor-binding protein secretion by a murine mammary epithelial cell line. Exp Cell Res 209:183-188.
99. Soler AP, Alemany J, Smith RM, de Pablo F, Jarett L. 1990. The state of differentiation of embryonic chicken lens cells determines insulin-like growth factor I internalization. Endocrinology 127:595-603.
100. Suikkari AM, Baxter RC. 1992. Insulin-like growth factor-binding protein-3 is functionally normal in pregnancy serum. J Clin Endocrinol Metab 74:177-183.
101. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF, Brattain MG. 1994. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269:26449-26455.
102. Tsukada T, Eguchi K, Migita K, Kawabe Y, Kawakami A, Matsuoka N, Takashima H, Mizokami A, Nagataki S. 1995. Transforming growth factor beta 1 induces apoptotic cell death in cultured human umbilical vein endothelial cells with down-regulated expression of bcl-2. Biochem Biophys Res Commun 210:1076-1082.
103. Turner R, Tjian R. 1989. Leucine repeats and an adjacent DNA binding domain mediate the formation of functional cFos-cJun heterodimers. Science 243:1689-1694.
104. Valentinis B, Bhala A, Deangelis T, Baserga R, Cohen P. 1995. The human insulin-like growth factor (IGF)-binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9:361-367.
105. Wakefield LM, Colletta AA, McCune BK, Sporn MB. 1992. Roles for transforming growth factors-beta in the genesis, prevention, and treatment of breast cancer. Cancer Treat Res 61:97-136.
106. Walker RA. 2000. Transforming growth factor beta and its receptors: their role in breast cancer. Histopathology 36:178-180.
107. Wang J, Han W, Zborowska E, Liang J, Wang X, Willson JK, Sun L, Brattain MG. 1996. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 271:17366-17371.
108. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. 2001. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86:1806-1813.
109. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C. 2000. Increased p53-dependent apoptosis by the insulin-like growth factor-binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 60:22-27.
110. Wilson EM, Oh Y, Rosenfeld RG. 1997. Generation and characterization of an IGFBP-7 antibody - identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J Clin Endocrinol Metab 82:1301-1303.
111. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA. 1998. Intranuclear localization of insulin-like growth factor-binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Invest Dermatol 111:239-242.
112. Xie SP, James SY, Colston KW. 1997. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells. J Endocrinol 154:495-504.
113. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. 1999. Characterization of insulin-like growth factor-binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140:1319-1328.
114. Yang YW-H, Yanagishita M, Rechler MM. 1996. Heparin inhibition of insulin-like growth factor-binding protein-3 binding to human fibroblasts and rat glioma cells - role of heparan sulfate proteoglycans. Endocrinology 137:4363-4371.
115. Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, Lippman ME, Rosen N. 1989. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 3:509-517.
116. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. 1999. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91:151-156.
117. Zadeh SM, Binoux M. 1997. The 16-kDa proteolytic fragment of insulin-like growth factor (IGF)-binding protein-3 inhibits the mitogenic action of fibroblast growth factor on mouse fibroblasts with a targeted disruption of the type 1 IGF receptor gene. Endocrinology 138:3069-3072.
118. Zhang XK, Liu Y, Lee MO. 1996. Retinoid receptors in human lung cancer and breast cancer. Mutat Res 350:267-277.